More European HTA collaboration, but no plans for a EuroNICE
This article was originally published in Scrip
The European Commission is calling for greater European cooperation in healthcare technology assessments but the spectre of a EuroNice is unlikely to haunt Europe quite yet. Although more collaboration to reduce the 27 plus "hurdles to market access" is on the cards, industry may be relieved that a central "EuroNICE" body ruling on cost-effectiveness looks unlikely.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.